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Abstract
Background: This study identifies factors that influence satisfaction with an insulin delivery system (IDS).
Knowledge of such factors could help identify individuals who would benefit from innovative IDS.
Methods: Individuals with type 2 diabetes who use insulin, recruited from a general and chronic illness panel,
participated in a web-based survey that included questions about demographics, self-reported diagnoses and
hemoglobin A1c (HbA1c), current IDS used, insulin therapy attitudes, current IDS features, and satisfaction with
IDS. Univariate analyses identified variables associated with IDS satisfaction (P< 0.05); those variables were
entered into stepwise linear regression analyses with IDS satisfaction as the dependent variable.
Results: Six hundred sixty-seven individuals with type 2 diabetes participated (mean age, 57 years; 52% female;
88% Caucasian; 73% vial=syringe users, 27% insulin pen users). IDS satisfaction was associated (P< 0.05) with
gender, health status, HbA1c, self-reported comorbidity, insulin therapy attitudes, IDS type, and evaluation of IDS
features. Among individuals who reported their HbA1c (n¼ 438), the best predictors of IDS satisfaction were
perceived effectiveness and value of insulin therapy, evaluation of IDS activity interference, and commitment to
insulin therapy (R2¼ 0.49, P< 0.001). Among all participants (n¼ 667), a second regression analysis that employed
a variable representing report of HbA1c found the best predictors of IDS satisfaction included those in the first
analysis with the addition of gender, report of HbA1c, and evaluation of IDS ease of use. These variables provided
additional variance (R2¼ 0.56, P< 0.001).
Conclusions: In people with type 2 diabetes, positive perceptions and attitudes about insulin therapy have
greater influence than the type of IDS used on IDS satisfaction.
Background
During 1999–2000, an estimated 3 million individualswith type 2 diabetes in the United States were using
insulin alone or in combination with oral antidiabetes medi-
cations.1 Prior to the introduction of the insulin pen in the
mid-1980s, the only insulin delivery option for patients with
diabetes was the vial and syringe (v=s). Insulin pens have
advantages over v=s that include portability, discreteness,
and, in some cases, accuracy of dosing.2–5 Crossover studies
comparing insulin pens with v=s indicate that 70–90% of pa-
tients are more satisfied with and=or prefer the insulin pen
over v=s.6–11 Reasons for patient satisfaction=preference in-
clude less fear of injection6 or pain of injection,7,9,10 confidence
in use and ease of use,6–10 discreteness in public,6,8 quicker
administration,10,11 and portability.11 Results of these studies
suggested that greater satisfaction with or preference for an
insulin pen would translate into better adherence and ulti-
mately better outcomes.6–11
In many European countries and in Japan, insulin pens are
the preferred mode of insulin delivery, with up to three-
fourths of insulin prescriptions written for pen devices. In
comparison, fewer than one in 20 insulin prescriptions in the
United States are for insulin pens.4 Physician recommen-
dation of insulin pens is a strong predictor of whether pa-
tients with type 2 diabetes use an insulin pen.12 Speculation is
that physicians in the United States do not recommend or
prescribe insulin pens because they lack formal training in
pen use, believe pens are just novelty or convenience,2 and=or
do not regard pens as a mechanism for improved patient
outcomes.12 Physicians in the United States might be more
likely to recommend insulin pens for patients with type 2
diabetes if they could identify patients who would benefit
from pen use.
1Global Health Outcomes, Eli Lilly and Company, Indianapolis, Indiana.
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Diabetes treatment satisfaction has been linked to better
treatment adherence,13 and, in turn, better adherence has been
linked to better outcomes.14–19 Understanding what contrib-
utes to insulin delivery system (IDS) satisfaction is the initial
step to identifying patients who would benefit from insulin
pens. Studies have shown that individual characteristics can
affect patient satisfaction regardless of the inherent properties
of the item being evaluated. For example, patients’ satisfac-
tion with their physicians is associated with perceived health
and psychosocial adaptation to diabetes.20 Satisfaction with
dietary management can be influenced by age, gender, depres-
sion, and employment status.21 Correlates of diabetes treat-
ment satisfaction22 and, more specifically, insulin therapy
satisfaction include hemoglobin A1c (HbA1c), age, and co-
morbidities.23,24 We hypothesize that some patient charac-
teristics contribute to IDS satisfaction independent of IDS. The
identification of these patient characteristics could facilitate
identifying patients who would most benefit from insulin pen
use.
The objective of this study is to address the following two
research questions:
1. For persons with type 2 diabetes using v=s only or an
insulin pen, what characteristics are significantly asso-
ciated with their IDS satisfaction?
2. Of the characteristics identified in question 1, which are
the best predictors of IDS satisfaction?
Subjects and Methods
Study design and participants
This study was an internet-based survey of individuals
with type 2 diabetes and using insulin conducted in early
2006. Participants were recruited from a large U.S. general
and chronic illness panel. Panel members consented to par-
ticipate in a study when they signed up and agreed to be part
of the panel online and again when they responded to a
confirmation e-mail.
Respondent eligibility criteria were (1) current diabetes
therapy must include at least one daily injection of insulin, (2)
must have used a v=s or an insulin pen for at least 3 months
but not longer than 10 years, (3) must never have participated
in an inhaled insulin trial, and (4) must not be currently par-
ticipating in a diabetes clinical trial.
E-mail invitations were sent to 11,883 adults in the gen-
eral and chronic illness panel; 4,150 adults (35%) responded
to the e-mail invitation, and 681 (16%) were eligible for the
study and completed the survey. However, 14 respondents
indicated in their survey responses that they injected their
insulin less than once a day. Those 14 respondents were
eliminated from further analysis, resulting in a total sample
of 667.
Web-based survey
The web-based survey included items about demograph-
ics, health status, 12 diagnoses, IDS used, frequency of injec-
tion, and self-reported HbA1c. The survey also included items
to assess attitudes about insulin therapy and IDS satisfaction
(Table 1). Finally, participants were asked to evaluate their
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IIP-q
The IIP-q consists of three subscales: Ease of Use, Activity
Interference, and Social Acceptability. Respondents are asked
the extent to which they agree that an IDS has features such as
ease of selecting doses, convenience, and not noticeable to
others when used. The IIP-q has demonstrated reliability and
validity.25 For purposes of this study, the IIP-q recall period
was designated as 4 weeks, the response set was increased
from a 5- to a 7-point scale ranging from ‘‘Strongly Disagree’’
(1) to ‘‘Strongly Agree’’ (7), and one item was eliminated.
Statistical analysis
To provide uniform scoring across the measures of atti-
tudes about insulin therapy and IIP-q subscales, all scores
were converted to a 0 to 100 scale through a linear transfor-
mation ([actual raw score lowest possible score=raw score
range]100). Participant characteristics for two IDS subgroups
(v=s users only and insulin pen users) and two HbA1c sub-
groups (participants who reported their HbA1c and those
who did not) were compared using w2 test (categorical vari-
ables) or t test of independent means.
To address the first research question concerning the as-
sociation between IDS satisfaction and individual character-
istics, attitudes, and IIP-q scores, either Pearson Product
Moment correlation coefficients were calculated, or a compar-
ison of independent means (independent t tests or one-way
analyses of variance) was performed.
To address the second research question concerning pre-
dictors of IDS satisfaction, stepwise linear regression analyses
with IDS satisfaction as the dependent variable were per-
formed. Independent variables were survey variables that
were significantly (P< 0.05) associated with IDS satisfaction.
Results
Study participants
The average age of all study participants (n¼ 667) was
approximately 57 years; 48% were male, and 88% were Cau-
casian (Table 2). Duration of diabetes for most participants
was 5 or more years, and 85% had been on insulin therapy for
1 year or longer. Of the 12 diagnoses listed in the survey, the
most frequently reported (in 15–45% of participants) were
depression, uncontrolled hypertension, neuropathy, heart
attack, congestive heart failure, and gallbladder disease. Se-
venteen percent of participants indicated that they had ‘‘none’’
of the 12 diagnoses.
The majority of participants (65%) selected the word
‘‘committed’’ to describe themselves with regard to their in-
sulin therapy. Participants’ attitudes toward insulin therapy
were relatively positive, with mean scores above 60 (on a 0 to
100 scale) for the measures of self-efficacy, perceived effec-
tiveness, and perceived value (Table 2).
About two-thirds (66%) of participants reported an HbA1c
value; of those, only 35% reported an HbA1c <7%, the treat-
ment goal endorsed by the American Diabetes Association.26
Compared with those who did not report an HbA1c value,
individuals who did report an HbA1c value tended to have
longer duration of diabetes, use an insulin pen, inject more
times a day, be employed full time, and have a higher income
(all P< 0.05). No significant differences were found in atti-
tudes about insulin therapy or IIP-q scores between the two
groups.
The majority (73%) of participants used a v=s for insulin
delivery, 14% used an insulin pen only, and 13% used both
(Table 2). If participants used both an insulin pen and a v=s for
insulin delivery, they were asked to refer only to the insulin
pen as they completed the IIP-q and responded to the IDS
satisfaction items; hereinafter, they are referred to as insulin
pen users. Insulin pen users reported better health status and
more full-time employment than v=s users; in addition, a
greater proportion of insulin pen users than v=s users re-
ported their HbA1c (Table 2).
Research Question 1: What individual characteristics
are associated with IDS satisfaction?
Correlation analyses. Significant (P< 0.05) relationships
were found between IDS satisfaction and age, self-reported
health status, self-reported HbA1c, insulin therapy attitudes,
and the three IIP-q subscale scores (Table 3). Greater IDS
satisfaction was significantly associated with older age, a
perception of better health status, self-reporting lower HbA1c,
having more positive attitudes about insulin therapy, and a
more positive evaluation of current IDS.
Test of independent means. No significant differences in
IDS satisfaction were found between groups for the following
variables: duration of diabetes, time on insulin therapy, in-
jections per day, ethnicity, employment status, education, or
income.
Significantly greater (P< 0.05) IDS satisfaction was found
to be associated with being female, self-reporting having ei-
ther none of the survey diagnoses or having no diagnosis of
neuropathy or depression, describing oneself as committed to
insulin therapy, using an insulin pen, and reporting an HbA1c
value (Table 4).
Research Question 2: What individual characteristics
and perceptions of features of an IDS significantly
predict IDS satisfaction?
Linear regression analyses. Because self-reported HbA1c
met the criteria for inclusion in the regression analyses (as-
sociation with IDS satisfaction at the P< 0.05 level) and data
on self-reported HbA1c were available for only 438 respon-
dents, the first stepwise linear regression analysis was per-
formed with only those 438 participants. The results indicated
that the best predictor of IDS satisfaction is perceived effec-
tiveness (R2¼ 0.361, P< 0.001), followed by activity interfer-
ence (R2 change¼ 0.091, P< 0.001), perceived value (R2
change¼ 0.032, P< 0.001), and self-description regarding in-
sulin therapy (R2 change¼ 0.007, P¼ 0.016), for a total
R2¼ 0.49, P< 0.001 (Table 5).
Because self-reported HbA1c was not a significant predic-
tor of IDS satisfaction in the first regression model, a second
stepwise linear regression analysis using all 667 participants
was performed. To account for differences in characteristics of
participants who reported their HbA1c and those who did
not, a new variable was added in the second stepwise re-
gression analysis to represent whether participants reported
their HbA1c.
Results of the second stepwise linear regression analysis
indicated that the best predictor of IDS satisfaction was
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Table 2. Characteristics and Mean Attitude About Insulin Therapy Scores of 667 Individuals with Type 2
Diabetes Who Use Insulin and Who Participated in a Web-Based Survey by IDS Used
v=s only (n¼ 489) Insulin pen (n¼ 178) Total (n¼ 667)
Mean SD Mean SD Mean SD P value
Age (years) 57.1 9.3 56.3 10.0 56.9 9.5 0.31
Self-reported health statusa 2.4 0.8 2.6 0.9 2.4 0.9 0.02
Number % Number % Number % P value
Male 239 49 79 44 318 48 0.34
Caucasian 432 88 155 87 587 88 0.69
Duration of diabetes
6 months to <5 years 68 14 22 12 90 14 0.86
5 years to <10 years 195 40 71 40 266 40
10 years 226 46 85 48 311 47
Duration of insulin therapy
3 months to <1 year 66 14 32 18 98 15 0.30
1 year to <5 years 260 53 86 48 346 52
5 years to <10 years 163 33 60 34 223 33
Number of injections per day
Once a day 190 39 28 16 218 33 <0.001
Twice a day 165 34 73 41 238 36
More than twice a day 134 27 77 43 211 32
Self-reported diagnoses (yes)
Depression 227 46 70 39 297 45 0.11
Uncontrolled hypertension 179 37 59 33 238 36 0.47
Neuropathy 180 37 52 29 232 35 0.08
Heart attack 95 19 24 14 119 18 0.09
Congestive heart failure 85 17 23 13 108 16 0.19
Gallbladder disease 74 15 27 15 101 15 1.00
None of 12 diagnoses 73 15 37 21 110 17 0.08
Highest educational level
High school or less 91 19 38 21 129 19 0.14
Some college 250 51 75 42 325 49
Undergraduate degree or some graduate school 93 19 36 20 129 19
Postgraduate degree 55 11 29 16 84 13
Full-time employment 125 26 64 36 189 28 0.01
Income (n¼ 600)
$24,999 or less 120 27 39 25 159 27 0.06
$25,000–$49,999 156 35 43 28 199 33
$50,000–$74,999 95 21 34 22 129 22
$75,000 or more 73 16 40 26 113 19
Attitudes about insulin therapy
Self-description
Committed 312 64 120 67 432 65 0.30
Tentative 30 6 8 5 38 6
Hopeful 81 17 21 12 102 15
Hassled 33 7 10 6 43 6
Overwhelmed 20 4 10 6 30 5
None of these 13 3 9 5 22 3
Mean SD Mean SD Mean SD P value
Self-efficacyb 64.2 21.8 65.3 22.5 64.5 22.0 0.55
Perceived effectivenessb 67.2 20.6 69.0 20.5 67.7 20.6 0.31
Perceived valueb 72.7 26.3 73.3 26.0 72.8 26.2 0.77
Number % Number % Number % P value
Self-reported HbA1c
Reported HbA1c (yes, %) 308 63 130 73 438 66 0.02
HbA1c <7.0% (yes, %) 101 33 52 40 153 35 0.16
HbA1c (%) (mean, SD) 7.6 1.5 7.3 1.2 7.5 1.4 0.02
Some total percentages may not equal 100% due to rounding error. Differences in categorical variables (e.g., income, education) between
v=s users and insulin pen users were tested using a w2 test. Differences in means of continuous variables (e.g., age, attitudes) between v=s
users and insulin pen users were tested using comparisons of independent means (t test or one-way analysis of variance).
aScores range from 1 to 5. Higher scores correspond to better perceived health status.
bScores range from 0 to 100. Higher scores correspond to a more positive attitude.
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perceived effectiveness (R2¼ 0.401, P< 0.001), followed by
activity interference (R2 change¼ 0.103, P< 0.001), perceived
value (R2 change¼ 0.028, P< 0.001), and self-description re-
garding insulin therapy (R2 change¼ 0.012, P< 0.001). How-
ever, in this second model, predictors of IDS satisfaction also
included the variable indicating whether participants re-
ported their HbA1c (R2 change¼ 0.005, P¼ 0.005), gender (R2
change¼ 0.003, P¼ 0.028), and ease of use (R2 change¼ 0.003,
P¼ 0.028), for a total R2¼ 0.556 (P< 0.001).
Discussion
This study aimed to identify those characteristics of indi-
viduals with type 2 diabetes using insulin that influence sat-
isfaction with their IDS. It was hypothesized that these
characteristics could assist in identifying patients who would
likely benefit from use of an insulin pen. This study is different
from preceding studies that compare IDSs in that (1) it re-
cruited from a national sample of individuals with type 2
diabetes who use insulin and (2) it examined associations
between participants’ satisfaction with their IDS and variables
shown to contribute to other types of satisfaction or prefer-
ences, such as satisfaction with physician relationship, dietary
management, diabetes treatment, and insulin therapy.20–24
Indicators of health status, both mental (e.g., depression)
and physical (e.g., neuropathy), were significantly associated
with IDS satisfaction, independent of the type of IDS used.
Depression has been shown to affect not only different types
of satisfaction but also medication adherence.19,27–31 Symp-
toms associated with depression, such as apathy toward di-
abetes management,32 may contribute to a poor perception of
an IDS independent of the system used. For such individuals,
their depression should be addressed before determining
which IDS best fits their needs.19
Brod et al.24 identified neuropathy as the single best pre-
dictor of insulin therapy satisfaction. It is possible that pain
and other symptoms of neuropathy make any injectable IDS
difficult for patients with neuropathy. Alternative methods of
delivery currently under development (inhaled, intranasal,
transdermal, and oral3) may be more appropriate for these
patients. Despite significant associations found between
health status indicators and participants’ evaluations of and
satisfaction with their IDS, none of these variables emerged as
significant predictors of IDS satisfaction. This result may have
been due to the fact that these health status variables (such as
self-reported health status and depression) were moderately
correlated with variables that did predict IDS satisfaction
(data not shown) and, therefore, did not provide unique
variance.
For the 438 participants who self-reported their HbA1c,
relatively small but significant associations were found be-
tween their reported HbA1c values and IDS satisfaction. Yet,
consistent with the study of insulin therapy satisfaction by
Brod et al.24 using an HbA1c laboratory value, HbA1c lost its
significance when combined with other variables. Like health
status indicators, self-reported HbA1c is moderately correlated
with variables that did significantly predict IDS satisfaction.
Not surprisingly, perceived effectiveness and value, along
with self-efficacy and commitment to insulin therapy, were
found to be significantly associated with IDS satisfaction. A
previous study has indicated that perceived effectiveness is a
key driver of diabetes treatment satisfaction and prefer-
ence.33,34 Confidence or self-efficacy has been purported to
contribute to improved diabetes self management.19,35–37 Sa-
voca et al.38 used qualitative methods to contrast the experience
and attitudes of people at the extremes of glycemic control. The
individuals labeled as ‘‘committed’’ were described by the au-
thors as consistent in their adherence to dietary, lifestyle, glu-
cose monitoring, and medication recommendations and were
consequently in better glycemic control than other groups of
individuals (these other groups were characterized as tentative,
Table 3. Correlations (r) Between IDS Satisfaction
and Patient Characteristics, Attitude Scores, and IIP-q
Scores Obtained Through a Web-Based Survey of 667





Self-reported health status 0.20**






Perceived value of insulin therapy 0.46**
Self-reported HbA1ca 0.31**
Ease of use 0.54**
Activity interference 0.53**
Social acceptability 0.44**
*P< 0.05, **P< 0.01.
an¼ 438.
Table 4. Mean IDS Satisfaction Scores Across
Characteristics Obtained Through a Web-Based
Survey of 667 Individuals with Type 2
Diabetes Who Use Insulin
Independent variable
IDS satisfaction
[mean (SD)] P value
Gender
Male (n¼ 318) 67.2 (24.6) 0.027
Female (n¼ 349) 71.4 (24.0)
Diagnosis of depression
Yes (n¼ 297) 65.5 (25.5) <0.001
No (n¼ 370) 72.6 (23.0)
Diagnosis of nephropathy
Yes (n¼ 232) 66.9 (24.7) 0.049
No (n¼ 435) 70.8 (24.1)
Self-report of 12 diagnoses
One or more diagnoses
(n¼ 557)
68.4 (24.4) 0.013





Other (n¼ 235) 55.7 (26.0) <0.001
Committed (n¼ 432) 76.9 (19.8)
Insulin delivery system
v=s only (n¼ 489) 66.9 (24.6) <0.001
Insulin pen (n¼ 178) 76.5 (22.3)
Self-reported HbA1c
No (n¼ 229) 66.0 (26.0) 0.010
Yes (n¼ 438) 71.2 (23.3)
PREDICTORS OF IDS SATISFACTION 423
hopeful, hassled, and overwhelmed). Moreover, an optimistic
attitude is believed to differentiate between those patients with
diabetes who are active problem solvers31,37,39 in their diabetes
management and those who are not. It may be that those in-
dividuals who described themselves as ‘‘committed’’ have a
more positive attitude about their health and their insulin
therapy, which translates into greater satisfaction independent
of the IDS used.
Results of the linear regression analysis that was limited to
those participants reporting an HbA1c value (n¼ 438) identi-
fied insulin therapy attitudes and perceptions of IDS features
as predictors of IDS satisfaction independent of IDS used.
When participants who did not report an HbA1c value were
added to the analysis, the first four predictors of IDS satisfac-
tion (perceived effectiveness, activity interference, perceived
value, and commitment to insulin therapy) remained signifi-
cant predictors. However, three additional variables were also
identified as significant predictors: gender, report of HbA1c,
and the extent to which participants agreed that their IDS was
easy to use.
In a review of the quality of life literature, Rubin and
Peyrot40 also found gender differences in treatment satisfac-
tion. In contrast to this study, they reported that males were
more satisfied with their treatment regimens and perceived
less impact of treatment regimen on their leisure activities than
females. Further research is needed to understand whether
gender difference in IDS satisfaction is clinically meaningful.
In a cross-sectional study of individuals with type 2 dia-
betes in the United States, Heisler et al.41 found that only one-
third could report their HbA1c values and that only a quarter
could do so accurately. Those individuals who knew their
HbA1c were better educated and reported a better under-
standing of their diabetes care. In this study, approximately
two-thirds of respondents reported their HbA1c value, but the
accuracy of those values is unknown. It was beyond the scope
of this study to compare the differences in understanding of
diabetes care between those who reported their HbA1c and
those who did not. This study did show, however, that pur-
ported knowledge of HbA1c played a significant role in IDS
satisfaction. Perhaps those who reported their HbA1c have a
better understanding of their disease progression and are
more accepting of what is required of them to manage their
diabetes in terms of diet, exercise, self-testing, and medication
adherence. If these participants believe an IDS is a tool to
assist them in achieving glycemic control, it may also lead to
greater IDS satisfaction. Further research is needed to un-
derstand this unanticipated finding.
Similar to studies showing greater patient satisfaction with
or preference for an insulin pen over a v=s,6–11 significant
differences were found in IDS satisfaction between v=s only
users and insulin pen users. However, IDS type did not
emerge as a significant predictor of IDS satisfaction. This re-
sult suggests that not all individuals with type 2 diabetes who
use insulin would be more satisfied with or would benefit
from using an insulin pen.
Limitations
This was a web-based survey, and recruitment was from a
population that has shown interest in participating in surveys;
thus findings cannot be generalized to the entire U.S. popu-
lation of individuals with type 2 diabetes. Effort was made to
ensure that all regions of the country were represented, but
this was an unweighted sample. Other limitations include the
fact that diagnoses and HbA1c were self-reported and could
not be confirmed.
Conclusions
Because many physicians are reluctant to prescribe pens, it
is important to identify characteristics and=or attitudes of in-
dividuals with type 2 diabetes who might benefit from using
an insulin pen. Although the results of this study did not
definitively identify a target population for insulin pens, it
does provide an initial step in this identification. These results
suggest that individuals with mental health or psychosocial
issues need to have these issues addressed prior to consider-
ation of IDS. Further, those individuals with physical issues
such as neuropathy may find both v=s and insulin pen chal-
lenging and would be better served using non-injectable al-
ternatives as they become available. However, individuals
whose attitudes indicate they value their insulin therapy and
are committed to their diabetes management may benefit
from insulin pen use. The reduced burden of treatment de-
rived from a pen2,12 may allow these individuals to achieve
and=or maintain the glycemic control they need for improved
patient outcomes.42
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2. Activity interference 0.27** 0.24***








(yes¼ 1, no¼ 0)
0.07**
6. Gender (male¼ 1,
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7. Ease of use 0.09*
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